Telehealth Response for E-prescribing Addiction Therapy Services Act

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act S. 923 - Better Mental Health Care for Americans Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R. 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act H.R. 4189/S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S.1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act Support implementation of Medicare code G2211 S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 4338 - Pay PCPs Act of 2024 H.R. 8261 - Preserving Telehealth, Hospital, and Ambulance Access Act Issues related to Medicare Part B reform Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Include nurses, APRNs, and nursing students in all national public health plans Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Extension of CMS waivers beyond the COVID-19 Public Health Emergency Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Documentation of medical records Use of clinician home address on Medicare claims when providing telehealth services

Client expense: $470,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7266/S. 3770 - Future Advancement of Academic Nursing (FAAN) Act H.R. 7153/S. 3679 - Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 7002/S. 2815 - Nurse Faculty Shortage Reduction Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 4534/S. 2245 - the Women and Lung Cancer Research and Preventive Services Act H.R. 5829 - Health Care Practitioner Disaster Protection Act S. 923 - Better Mental Health Care for Americans Act H.R. 3768/S. 1851 - Midwives for MOMs Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2411/S. 1150 - National Nursing Workforce Center Act of 2023 H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 3523/S. 1710 - Perinatal Workforce Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3355 - Substance Use Disorder Treatment and Recovery Loan Repayment Program Reauthorization Act of 2023 S. 1627 - Providing Real-World Education and Clinical Experience by Precepting Tomorrows Nurses Act (PRECEPT) Nurses Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 3730/S. 198 - Rural Health Clinic Burden Reduction Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S. 1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.Con.Res.42 - Honoring Mary Eliza Mahoney, America's first professionally trained Black nurse. S.Res.201/H.Res.375 - A resolution supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2023. H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 Support funding for the National Health Service Corps S. 862 - Restoring Americas Health Care Workforce and Readiness Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.Res. 676/H.Res. 1208 - a resolution supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2024 S. 4338 - Pay PCPs Act of 2024 H.R. 9133/S. 4835 - Primary and Behavioral Health Care Access Act H.R. 6860/S. 5018 - the Restore Protections for Dialysis Patients Act H.R. 10280 - Strengthening Pathways to Health Professions Act Issues related to Medicare Part B reform Issues related to enhancing access to care at home in rural and underserved communities Support for the creation of the Office of Caregiver Health Support a final rule prohibiting menthol cigarettes and cigars Support implementation of Medicare code G2211 Extending COVID-19 waivers related to nurse practitioners and critical access hospitals Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Nursing education Include nurses, APRNs, and nursing students in all national public health plans Public health and nursing workforce infrastructure Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Provide resources to support nurses, APRNs, and nursing students mental health needs, especially for those responding to the pandemic Extension of CMS waivers beyond the COVID-19 Public Health Emergency Use of telehealth to prescribe controlled substances under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [Public Law No: 110-425] Site specific restrictions on providers under DEA controlled substances policy Implementation of the Medication Access and Training Expansion (MATE) Act Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Primary care payment reform Documentation of medical records Inclusion of NPs in the HPSA bonus program for clinicians practicing in primary care HPSAs Framework reform of the National Institutes of Health and the National Institute of Nursing Research Optimizing the Food and Drug Administration's Use of and Processes for Advisory Committees

Client expense: $470,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of, White House Office

Affordable Care Act (ACA), ACA subsidies and tax credits; Telehealth/ telehealth flexibilities; Mental Health Care; Youth Mental Health; Site neutral payment reform; hospital billing; Transparency in coverage; Surprise Billing; Prior Authorization; Hospital Consolidation; Health Equity Index reward factor; Employer-provided health coverage; Cyber attack & Cybersecurity; Provider Directories; Artificial Intelligence; Health Equity; Maternal Health; ACA fraud; 2025 Proposed NBPP/Individual Market/ACA exchanges; Rural healthcare; CMS Transforming Maternal Health (TMaH) model; Data Equity; No surprises enforcement S. 1451 Healthy Competition for Better Care Act To ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care. Sponsor: Sen. Braun, Mike [R-IN] H.R.3120 - Healthy Competition for Better Care Act To ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care. Sponsor: Rep. Steel, Michelle [R-CA-45] S. 3548 Health Care PRICE Transparency Act To amend the Public Health Service Act to provide for hospital and insurer price transparency. Sponsor: Sen. Braun, Mike [R-IN] H.R. 4818, Treat and Reduce Obesity Act To amend title XVIII of the Social Security Act to provide for the coordination of programs to prevent and treat obesity, and for other purposes. Sponsor: Rep. Wenstrup, Brad R. [R-OH-2] S.2407 - Treat and Reduce Obesity Act of 2023 To amend title XVIII of the Social Security Act to provide for the coordination of programs to prevent and treat obesity, and for other purposes. Sponsor: Sen. Carper, Thomas R. [D-DE] H.R.2630 - Safe Step Act To amend the Employee Retirement Income Security Act of 1974 to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. Sponsor: Rep. Wenstrup, Brad R. [R-OH-2] S.652 - Safe Step Act To amend the Employee Retirement Income Security Act of 1974 to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. Sponsor: Sen. Murkowski, Lisa [R-AK] S. 1001 Telehealth Expansion Act of 2023 To amend the Internal Revenue Code of 1986 to permanently extend the exemption for telehealth services from certain high deductible health plan rules. Sponsor: Sen. Daines, Steve [R-MT] H.R. 1843 - Telehealth Expansion Act To amend the Internal Revenue Code of 1986 to permanently extend the exemption for telehealth services from certain high deductible health plan rules. Sponsor: Rep. Steel, Michelle [R-CA-45] H.R. 4093, Remote Opioid Monitoring Act (House only) To provide for a study on the effects of remote monitoring on individuals who are prescribed opioids. Sponsor: Rep. Balderson, Troy [R-OH-12] H.R. 3305, Black Maternal Health Momnibus Act To end preventable maternal mortality, severe maternal morbidity, and maternal health disparities in the United States, and for other purposes. Sponsor: Rep. Underwood, Lauren [D-IL-14] S.1606 - Black Maternal Health Momnibus Act To end preventable maternal mortality, severe maternal morbidity, and maternal health disparities in the United States, and for other purposes. Sponsor: Sen. Booker, Cory A. [D-NJ] H.R.3226 - PREEMIE Reauthorization Act of 2023 To reauthorize the Prematurity Research Expansion and Education for Mothers who deliver Infants Early Act. Sponsor: Rep. Eshoo, Anna G. [D-CA-16] H.R.3838 - Preventing Maternal Deaths Reauthorization Act of 2023 To amend title III of the Public Health Service Act to reauthorize Federal support of States in their work to save and sustain the health of mothers during pregnancy, childbirth, and the postpartum period, to eliminate disparities in maternal health outcomes for pregnancy-related and pregnancy-associated deaths, to identify solutions to improve health care quality and health outcomes for mothers, and for other purposes. Sponsor: Rep. Burgess, Michael C. [R-TX-26] S.2415 - Preventing Maternal Deaths Reauthorization Act of 2023 To amend title III of the Public Health Service Act to reauthorize Federal support of States in their work to save and sustain the health of mothers during pregnancy, childbirth, and the postpartum period, to eliminate disparities in maternal health outcomes for pregnancy-related and pregnancy-associated deaths, to identify solutions to improve health care quality and health outcomes for mothers, and for other purposes. Sponsor: Sen. Capito, Shelley Moore [R-WV] S.1869 - SITE Act To amend title XVIII of the Social Security Act and title XXVII of the Public Health Service Act to ensure fair billing practice for items and services furnished by off-campus hospital locations, to amend such title XVIII to provide for payments for graduate nursing education costs, and for other purposes. Sponsor: Sen. Braun, Mike [R-IN] H.R.3417 - FAIR Act To ensure fair billing practices for items and services furnished by off-campus outpatient departments of a provider. Sponsor: Rep. Hern, Kevin [R-OK-1] H.R. 5378 Lower Costs, More Transparency Act To promote price transparency in the health care sector, and for other purposes. Sponsor: Rep. McMorris Rodgers, Cathy [R-WA-5] H.R.4531 - Support for Patients and Communities Reauthorization Act To reauthorize certain programs that provide for opioid use disorder prevention, recovery, and treatment, and for other purposes. Sponsor: Rep. Guthrie, Brett [R-KY-2] S.3393 - SUPPORT for Patients and Communities Reauthorization Act To reauthorize the SUPPORT for Patients and Communities Act, and for other purposes. Sponsor: Sen. Sanders, Bernard [I-VT] H.R.3630 - No Surprises Act To amend title XXVII of the Public Health Service Act to protect health care consumers from surprise billing practices, and for other purposes. Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] S.2016 - CONNECT for Health Act of 2023 To amend title XVIII of the Social Security Act to expand access to telehealth services, and for other purposes. Sponsor: Sen. Schatz, Brian [D-HI] H.R. 4189, CONNECT for Health Act To amend title XVIII of the Social Security Act to expand access to telehealth services, and for other purposes. Sponsor: Rep. Thompson, Mike [D-CA-4] H.R. 5012, SHINE for Autumn Act To improve research and data collection on stillbirths, and for other purposes. Sponsor: Rep. Kim, Young [R-CA-40] S.2647 - SHINE for Autumn Act of 2023 To improve research and data collection on stillbirths, and for other purposes. Sponsor: Sen. Booker, Cory A. [D-NJ] H.R. 6033, SPEAK Act To require the Secretary of Health and Human Services to establish a task force to improve access to health care information technology for non-English speakers. Sponsor: Rep. Steel, Michelle [R-CA-45] H.R. 4581, Maternal and Child Health Stillbirth Prevention Act To amend title V of the Social Security Act to support stillbirth prevention and research, and for other purposes. Sponsor: Rep. Hinson, Ashley [R-IA-2] S. 3430, Better Mental Health Care, Lower Cost Drugs, and Extenders Act To amend titles XVIII and XIX of the Social Security Act to expand the mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions under Medicare and Medicaid, and for other purposes. Sponsor: Sen. Wyden, Ron [D-OR] H.R. 5066, Tech to Save Moms Act To amend the Public Health Service Act to authorize grants to evaluate, develop, and expand the use of technology-enabled collaborative learning and capacity building models to improve maternal health outcomes, and for other purposes. Sponsor: Rep. Williams, Nikema [D-GA-5] S. 1384 - Living Donor Protection Act of 2023 To promote and protect from discrimination living organ donors. Sponsor: Sen. Gillibrand, Kirsten E. [D-NY] H.R. 2923 - Living Donor Protection Act of 2023 To promote and protect from discrimination living organ donors. Sponsor: Rep. Nadler, Jerrold [D-NY-12] S. 1573 - PREEMIE Reauthorization Act of 2023 To reauthorize the Prematurity Research Expansion and Education for Mothers who deliver Infants Early Act. Sponsor: Sen. Bennet, Michael F. [D-CO] H.R. 10545, American Relief Act, 2025 Making further continuing appropriations for the fiscal year ending September 30, 2025, and for other purposes. Sponsor: Rep. Cole, Tom [R-OK-4] H.R. 5163 TREATS Act To amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Sponsor: Rep. Trone, David J. [D-MD-6] S.3193 - TREATS Act To amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Sponsor: Sen. Whitehouse, Sheldon [D-RI] H.R. 4366, Consolidated Appropriations Act of 2024 This act provides FY2024 appropriations for several federal departments and agencies. It also extends several expiring programs and authorities, including various public health programs. Sponsor: Rep. Carter, John R. [R-TX-31]

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. Joined coalition letter urging passage of the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (H.R. 5819/S.1378), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. ASAM joined over 60 organization signatories in a letter to the Centers for Medicare and Medicaid Services (CMS) regarding proposed guidance and templates for parity compliance in Medicaid and the Children's Health Insurance Program (CHIP). Joined coalition letter encouraging CMS to strengthen the Medicaid parity regulations by aligning them with parity regulations recently finalized for commercial plans. The letter also recommended that CMS amend the templates and guidance documents to more closely align with the federal parity statute and regulations. Joined coalition letter requesting that Congress pass legislation to both prevent the scheduled 2.83 percent Medicare physician payment cut and, critically, provide a positive payment update for 2025.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Legislation and policies relating to: Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Reauthorization of the Childrens Health Insurance Program Reauthorization of the Child Nutrition Act Section 2706 of the ACA regarding provider non-discrimination Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Health information technology and electronic health records Mental health services and violence prevention H.R. 766/S 114, Dr. Michael C. Burgess Preventive Health Savings Act H.R. 1147/S. 1957, Whole Milk for Healthy Kids Act of 2023 H.R. 1843/S.1001, Telehealth Expansion Act of 2023 H.R. 2411/S. 1150, National Nursing Workforce Centers Act of 2023 H.R. 2663/S. 1176, Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 2713/S. 2418, Improving Care and Access to Nurses (I CAN) Act H.R. 2901, Food Labeling Modernization Act of 2023 H.R. 3073/S. 1452, Community Mental Wellness and Resilience Act of 2023 H.R 3226/S. 1573, PREEMIE Reauthorization Act of 2023 H.R. 3305/S. 1606, Black Maternal Health Momnibus Act H.R. 3331/S. 754, Improving Mental Health and Wellness in Schools Act H.R.3433, Give Kids a Chance Act H.R. 3633, Promoting Resources to Expand Vaccination, Education, and New Treatments for HPV Cancers (PREVENT HPV Cancers) Act of 2023 H.R. 4310/S. 2233, Youth Poisoning Protection Act H.R. 4581/S. 2231, Maternal and Child Health Stillbirth Prevention Act of 2023 H.R. 4758/S. 2372, Accelerating Kids Access to Care Act H.R. 4775, Helping Tobacco Users Quit Act H.R. 4892/S. 3921, Medicaid Bump Act H.R. 5012/S. 2647, Stillbirth Health Improvement and Education (SHINE) for Autumn Act of 2023 H.R. 5378, Lower Costs, More Transparency Act H.R. 5541, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act H.R. 6122/S. 2853, Train More Nurses Act H.R. 6149/S. 1291, Protecting Kids on Social Media Act H.R. 6766/S. 3512, Transparency, Readability, Understandability, Truth, and Helpfulness (TRUTH) in Labeling Act H.R. 6960/S. 3765, Emergency Medical Services for Children Reauthorization Act of 2024 H.R. 7002/S. 2815, Nurse Faculty Shortage Reduction Act of 2024 H.R. 7153/S. 3679, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 7224, To reauthorize the Stop, Observe, Ask, and Respond to Health and Wellness Training Program. H.R. 7808, Early Action and Responsiveness Lifts Youth (EARLY) Minds Act H.R. 8467, Farm, Food, and National Security Act of 2024 H.R. 8818, American Privacy Rights Act H.R. 9076, Protecting Americas Children by Strengthening Families Act H.R. 9425, Tobacco User Fee Modernization Act of 2024 H.R. 9774/S. 5194, Health Care Affordability Act of 2024 S. 397, Promoting Physical Activity for Americans Act S.644/H.R. 1359, Modernizing Opioid Treatment Access Act S. 1409/H.R. 7891, Kids Online Safety Act S. 1418/H.R. 7890, Children and Teens Online Privacy Protection Act S. 1840/H.R. 3916, Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act of 2023 S. 1884/H.R. 3713, Mental Health Services for Students Act of 2023 S. 2073, Kids Online Safety and Privacy Act S. 2840, Bipartisan Primary Care and Health Workforce Act S. 3085, Preventing Adverse Childhood Experiences (PACE) Act S. 3193/H.R. 5163, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act S. 3393/H.R. 4531, SUPPORT for Patients and Communities Reauthorization Act S. 3770/H.R. 7266, Future Advancement of Academic Nursing (FAAN) Act S. 4041, Creating Access and Resources in Education (CARE) for Student Mental Health Act S. 4532/H.R. 8702, Improving Seniors Timely Access to Care Act S. 4745, Federal Food Administration Act

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7266/S. 3770 - Future Advancement of Academic Nursing (FAAN) Act H.R. 7153/S. 3679 - Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 7002/S. 2815 - Nurse Faculty Shortage Reduction Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 4534/S. 2245 - the Women and Lung Cancer Research and Preventive Services Act H.R. 5829 - Health Care Practitioner Disaster Protection ActS. 923 - Better Mental Health Care for Americans Act H.R. 3768/S. 1851 - Midwives for MOMs Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2411/S. 1150 - National Nursing Workforce Center Act of 2023 H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 3523/S. 1710 - Perinatal Workforce Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3355 - Substance Use Disorder Treatment and Recovery Loan Repayment Program Reauthorization Act of 2023 S. 1627 - Providing Real-World Education and Clinical Experience by Precepting Tomorrows Nurses Act (PRECEPT) Nurses Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 3730/S. 198 - Rural Health Clinic Burden Reduction Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S. 1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.Con.Res.42 - Honoring Mary Eliza Mahoney, America's first professionally trained Black nurse. S.Res.201/H.Res.375 - A resolution supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2023. H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 Support funding for the National Health Service Corps S. 862 - Restoring Americas Health Care Workforce and Readiness Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.Res. 676/H.Res. 1208 - a resolution supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2024 S. 4338 - Pay PCPs Act of 2024 H.R. 9133/S. 4835 - Primary and Behavioral Health Care Access Act H.R. 6860/S. 5018 - the Restore Protections for Dialysis Patients Act Issues related to Medicare Part B reform Issues related to enhancing access to care at home in rural and underserved communities Support for the creation of the Office of Caregiver Health Support a final rule prohibiting menthol cigarettes and cigars Support implementation of Medicare code G2211 Extending COVID-19 waivers related to nurse practitioners and critical access hospitals Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Nursing education Include nurses, APRNs, and nursing students in all national public health plans Public health and nursing workforce infrastructure Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Provide resources to support nurses, APRNs, and nursing students mental health needs, especially for those responding to the pandemic Extension of CMS waivers beyond the COVID-19 Public Health Emergency Use of telehealth to prescribe controlled substances under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [Public Law No: 110-425] Site specific restrictions on providers under DEA controlled substances policy Implementation of the Medication Access and Training Expansion (MATE) Act Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Primary care payment reform Documentation of medical records Inclusion of NPs in the HPSA bonus program for clinicians practicing in primary care HPSAs Framework reform of the National Institutes of Health and the National Institute of Nursing Research Optimizing the Food and Drug Administration's Use of and Processes for Advisory Committees

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of, White House Office

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act S. 923 - Better Mental Health Care for Americans Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act H.R. 4189/S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S.1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act Support implementation of Medicare code G2211 S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 4338 - Pay PCPs Act of 2024 H.R. 8261 - Preserving Telehealth, Hospital, and Ambulance Access Act Issues related to Medicare Part B reform Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Include nurses, APRNs, and nursing students in all national public health plans Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Extension of CMS waivers beyond the COVID-19 Public Health Emergency Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Documentation of medical records Use of clinician home address on Medicare claims when providing telehealth services

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 824 - "Telehealth Benefit Expansion for Workers Act of 2023"; HR 4189 "CONNECT for Health Act of 2023"; S. 2016 "CONNECT for Health Act of 2023"; HR 1843 - "Telehealth Expansion Act of 2023"; S. 1001 - "Telehealth Expansion Act of 2023"; HR 3432 - "Telemental Health Care Access Act of 2023"; HR 5163 "Telehealth Response for E-prescribing Addiction Therapy Services Act"; S. 3193 - "TREATS Act" Implementation of the Ryan Haight Act/DEA rulemaking on telemedicine. Advocate for the DEA to act in a timely manner to extend flexibilities for telemedicine prescribing of controlled substances.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 824 - "Telehealth Benefit Expansion for Workers Act of 2023"; HR 4189 "CONNECT for Health Act of 2023"; S. 2016 "CONNECT for Health Act of 2023"; HR 1843 - "Telehealth Expansion Act of 2023"; S. 1001 - "Telehealth Expansion Act of 2023"; HR 3432 - "Telemental Health Care Access Act of 2023"; HR 5163 "Telehealth Response for E-prescribing Addiction Therapy Services Act"; S. 3193 - "TREATS Act" Implementation of the Ryan Haight Act/DEA rulemaking on telemedicine. Advocate for the DEA to act in a timely manner to extend flexibilities for telemedicine prescribing of controlled substances.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7266/S. 3770 - Future Advancement of Academic Nursing (FAAN) Act H.R. 7153/S. 3679 - Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 7002/S. 2815 - Nurse Faculty Shortage Reduction Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 4534/S. 2245 - the Women and Lung Cancer Research and Preventive Services Act H.R. 5829 - Health Care Practitioner Disaster Protection ActS. 923 - Better Mental Health Care for Americans Act H.R. 3768/S. 1851 - Midwives for MOMs Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2411/S. 1150 - National Nursing Workforce Center Act of 2023 H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 3523/S. 1710 - Perinatal Workforce Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3355 - Substance Use Disorder Treatment and Recovery Loan Repayment Program Reauthorization Act of 2023 S. 1627 - Providing Real-World Education and Clinical Experience by Precepting Tomorrows Nurses Act (PRECEPT) Nurses Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 3730/S. 198 - Rural Health Clinic Burden Reduction Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S. 1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.Con.Res.42 - Honoring Mary Eliza Mahoney, America's first professionally trained Black nurse. S.Res.201/H.Res.375 - A resolution supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2023. H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 Support funding for the National Health Service Corps S. 862 - Restoring Americas Health Care Workforce and Readiness Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S.Res. 676/H.Res. 1208 - a resolution supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2024 S. 4338 - Pay PCPs Act of 2024 Issues related to Medicare Part B reform Issues related to enhancing access to care at home in rural and underserved communities Support for the creation of the Office of Caregiver Health Support a final rule prohibiting menthol cigarettes and cigars Support implementation of Medicare code G2211 Extending COVID-19 waivers related to nurse practitioners and critical access hospitals Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Nursing education Include nurses, APRNs, and nursing students in all national public health plans Public health and nursing workforce infrastructure Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Provide resources to support nurses, APRNs, and nursing students mental health needs, especially for those responding to the pandemic Extension of CMS waivers beyond the COVID-19 Public Health Emergency Use of telehealth to prescribe controlled substances under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [Public Law No: 110-425] Site specific restrictions on providers under DEA controlled substances policy Implementation of the Medication Access and Training Expansion (MATE) Act Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Primary care payment reform Documentation of medical records Inclusion of NPs in the HPSA bonus program for clinicians practicing in primary care HPSAs

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of, White House Office

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act S. 923 - Better Mental Health Care for Americans Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act H.R. 4189/S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S.1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act Support implementation of Medicare code G2211 S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 S. 4338 - Pay PCPs Act of 2024 Issues related to Medicare Part B reform Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Include nurses, APRNs, and nursing students in all national public health plans Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Extension of CMS waivers beyond the COVID-19 Public Health Emergency Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Documentation of medical records Use of clinician home address on Medicare claims when providing telehealth services

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Joined coalition letter opposing any legislation that would bar medical schools from receiving federal funding if they engage in activities such as having a Diversity, Equity and Inclusion (DEI) office and/or provide education on structural or institutional racism. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. Joined a coalition letter urging support of the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Joined a coalition letter requesting clear guidance from the relevant agencies that explicitly states that suspicious order reporting requirements will not be enforced against buprenorphine approved by the Food and Drug Administration (FDA) for OUD until further notice. Joined a coalition letter calling on the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Joined a coalition letter urging the House Appropriations Committee's approval of the full authorized level of tobacco user fees, and that they oppose any efforts to weaken or alter the Food and Drug Administration's authority over tobacco products in the appropriations process. Joined a coalition letter urging the Centers for Medicare and Medicaid Services (CMS) to improve data collection on access to substance use disorder (SUD) treatment and providers, and to use this data to continue to improve access to SUD treatment in both Medicare Advantage (MA) and traditional Medicare. The letter asks CMS to collect data on network adequacy, reimbursement rates and practices, utilization management, cost-sharing, and supplemental benefits. Sent a comment letter to HRSA on its draft program guidance regarding justice-involved individuals reentering the community ASAM noted the exclusion of pre-trial detainees from this guidance and called on HRSA rescind the omission. Sent a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding a proposed rule to implement 200 new residency/fellowship slots by fiscal year 2026. ASAM called on CMS to work with HRSA to revise the mental health health professional shortage area (HPSA) definition and related criterion to include clinicians that specialize in treating SUD. Joined a coalition letter requesting the Departments of Health and Human Services, Labor, and Treasury finalize the 2023 proposed parity regulations. Joined a coalition letter requesting $40 million for the Employee Security Benefits Administration (EBSA) within the Department of Labor (DOL) in the FY 2025 Labor-Health and Human Services (HHS) appropriations bill to review health plans' parity compliance analyses.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

HR 824 - "Telehealth Benefit Expansion for Workers Act of 2023"; HR 4189 "CONNECT for Health Act of 2023"; S. 2016 "CONNECT for Health Act of 2023"; HR 1843 - "Telehealth Expansion Act of 2023"; S. 1001 - "Telehealth Expansion Act of 2023"; HR 3432 - "Telemental Health Care Access Act of 2023"; HR 5163 "Telehealth Response for E-prescribing Addiction Therapy Services Act"; S. 3193 - "TREATS Act" Implementation of the Ryan Haight Act/DEA rulemaking on telemedicine.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 824 - "Telehealth Benefit Expansion for Workers Act of 2023"; HR 4189 "CONNECT for Health Act of 2023"; S. 2016 "CONNECT for Health Act of 2023"; HR 1843 - "Telehealth Expansion Act of 2023"; S. 1001 - "Telehealth Expansion Act of 2023"; HR 3432 - "Telemental Health Care Access Act of 2023"; HR 5163 "Telehealth Response for E-prescribing Addiction Therapy Services Act"; S. 3193 - "TREATS Act" Implementation of the Ryan Haight Act/DEA rulemaking on telemedicine.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Relayed community concerns regarding CDC National Harm Reduction TA Center; met with key Senate and House Staff regarding prevention of potential advancement of anti-Overdose Prevention Center amendments or bills. Supported Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act - H.R.5163.

Client expense: Not reported · Firm income: $40,000

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Office of Natl AIDS Policy, SENATE

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7266/S. 3770 - Future Advancement of Academic Nursing (FAAN) Act H.R. 7153/S. 3679 - Dr. Lorna Breen Health Care Provider Protection Reauthorization Act H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 7002/S. 2815 - Nurse Faculty Shortage Reduction Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 4534/S. 2245, the Women and Lung Cancer Research and Preventive Services Act H.R. 5829 - Health Care Practitioner Disaster Protection ActS. 923 - Better Mental Health Care for Americans Act H.R. 3768/S. 1851 - Midwives for MOMs Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2411/S. 1150 - National Nursing Workforce Center Act of 2023 H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act H.R. 3523/S. 1710 - Perinatal Workforce Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3355 - Substance Use Disorder Treatment and Recovery Loan Repayment Program Reauthorization Act of 2023 S. 1627 - Providing Real-World Education and Clinical Experience by Precepting Tomorrows Nurses Act (PRECEPT) Nurses Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 3730/S. 198 - Rural Health Clinic Burden Reduction Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S. 1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.Con.Res.42 - Honoring Mary Eliza Mahoney, America's first professionally trained Black nurse. S.Res.201/H.Res.375 - A resolution supporting the goals and ideals of National Nurses Week, to be observed from May 6 through May 12, 2023. H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 Support funding for the National Health Service Corps S. 862 - Restoring Americas Health Care Workforce and Readiness Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Support a final rule prohibiting menthol cigarettes and cigars Support implementation of Medicare code G2211 Extending COVID-19 waivers related to nurse practitioners and critical access hospitals Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Nursing education Include nurses, APRNs, and nursing students in all national public health plans Public health and nursing workforce infrastructure Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Provide resources to support nurses, APRNs, and nursing students mental health needs, especially for those responding to the pandemic Extension of CMS waivers beyond the COVID-19 Public Health Emergency Use of telehealth to prescribe controlled substances under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [Public Law No: 110-425] Site specific restrictions on providers under DEA controlled substances policy Implementation of the Medication Access and Training Expansion (MATE) Act Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Primary care payment reform Documentation of medical records

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Treasury, Dept of, White House Office

S. 260/H.R. 704 - Promoting Access to Diabetic Shoes Act H.R. 2583/S. 3481 - Increasing Access to Quality Cardiac Rehabilitation Care Act H.R. 2713/S. 2418 - Improving Care and Access to Nurses (ICAN) Act S. 3939/H.R. 7665 - ACO Assignment Improvement Act of 2024 H.R. 7623/S. 3967 - Telehealth Modernization Act H.R. 5163/ S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act S. 923 - Better Mental Health Care for Americans Act H.R. 3305/S. 1606 - Black Maternal Health Momnibus Act H.R. 2663/S. 1176 - Workplace Violence Prevention for Health Care and Social Service Workers Act S. 2085 - A bill to amend title XVIII of the Social Security Act to provide for Medicare coverage of multi-cancer early detection screening tests H.R 2407 - the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act H.R. 4189/S. 2016 - CONNECT for Health Act S. 1869 - Site-based Invoicing and Transparency Enhancement Act (SITE) Act H.R. 3623/S. 1586 - Educating Future Nurses Act H.R. 2829 - Chronic Care Management Improvement Act of 2023 H.R. 2400/S. 1165 - Reentry Act of 2023 S.1378 - Connecting Our Medical Providers with Links to Expand Tailored and Effective Care (COMPLETE Care) Act H.R. 4822 - Health Care Price Transparency Act of 2023 H.R. 4779 - Breast Cancer Patient Equity Act Primary Care and Health Workforce Expansion Act S. 2840 - Bipartisan Primary Care and Health Workforce Act S. 1976/H.R. 4104 - Preserving Patient Access to Home Infusion Act Support implementation of Medicare code G2211 S. 3297/H.R. 6407 - Medical Nutrition Therapy Act of 2023 S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 Skilled nursing facility admitting examination and assessment requirements Health plan coverage and program requirements, including provider non-discrimination, network adequacy and prior authorization Nursing faculty and workforce shortage Include nurses, APRNs, and nursing students in all national public health plans Rural health care issues, including rural workforce, COVID-19 vaccination, and reimbursement Addressing health equity Medication-Assisted Treatment (MATs) Issues relating to the mental and substance use disorder workforce Opioid epidemic COVID-19 Pandemic, including funding, personal protective equipment, testing and vaccines Extension of CMS waivers beyond the COVID-19 Public Health Emergency Telehealth, remote patient monitoring and other forms of health technology Reducing regulatory burdens, including those relating to Medicare Conditions of Participation Medicare provider reimbursement Documentation of medical records Use of clinician home address on Medicare claims when providing telehealth services

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Advocated for increased FY24 and FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 and FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its recent rules proposing policy changes in 2025 Medicare Advantage (MA) plans. ASAM joined coalition letter asking the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to change Medicare's custody definition to permit coverage for older adults and people with disabilities who are living in the community after incarceration or have other history with the criminal legal system. ASAM sent a letter to Senators Tammy Baldwin and Shelley Moore Capito with several other organizations, advocating the Senators oppose the addition of any language that would prohibit the National Institute on Drug Abuse (NIDA) from funding any research related to harm reduction in the Statement of Managers accompanying the Conference Agreement on the Fiscal 2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. ASAM signed a letter sent to the House sponsors of H.R. 7050 - the Substance Use Disorder (SUD) Workforce Act of 2024. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. ASAM joined more than 120 organizations in a statement urging the Biden Administration to finalize federal rules to eliminate menthol cigarettes and flavored cigars.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY24 and FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 and FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its recent rules proposing policy changes in 2025 Medicare Advantage (MA) plans. ASAM joined coalition letter asking the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to change Medicare's custody definition to permit coverage for older adults and people with disabilities who are living in the community after incarceration or have other history with the criminal legal system. ASAM sent a letter to Senators Tammy Baldwin and Shelley Moore Capito with several other organizations, advocating the Senators oppose the addition of any language that would prohibit the National Institute on Drug Abuse (NIDA) from funding any research related to harm reduction in the Statement of Managers accompanying the Conference Agreement on the Fiscal 2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. ASAM signed a letter sent to the House sponsors of H.R. 7050 - the Substance Use Disorder (SUD) Workforce Act of 2024. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. ASAM joined more than 120 organizations in a statement urging the Biden Administration to finalize federal rules to eliminate menthol cigarettes and flavored cigars.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY24 and FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 and FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its recent rules proposing policy changes in 2025 Medicare Advantage (MA) plans. ASAM joined coalition letter asking the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to change Medicare's custody definition to permit coverage for older adults and people with disabilities who are living in the community after incarceration or have other history with the criminal legal system. ASAM sent a letter to Senators Tammy Baldwin and Shelley Moore Capito with several other organizations, advocating the Senators oppose the addition of any language that would prohibit the National Institute on Drug Abuse (NIDA) from funding any research related to harm reduction in the Statement of Managers accompanying the Conference Agreement on the Fiscal 2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. ASAM signed a letter sent to the House sponsors of H.R. 7050 - the Substance Use Disorder (SUD) Workforce Act of 2024. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. ASAM joined more than 120 organizations in a statement urging the Biden Administration to finalize federal rules to eliminate menthol cigarettes and flavored cigars.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY24 and FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 and FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its recent rules proposing policy changes in 2025 Medicare Advantage (MA) plans. ASAM joined coalition letter asking the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to change Medicare's custody definition to permit coverage for older adults and people with disabilities who are living in the community after incarceration or have other history with the criminal legal system. ASAM sent a letter to Senators Tammy Baldwin and Shelley Moore Capito with several other organizations, advocating the Senators oppose the addition of any language that would prohibit the National Institute on Drug Abuse (NIDA) from funding any research related to harm reduction in the Statement of Managers accompanying the Conference Agreement on the Fiscal 2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. ASAM signed a letter sent to the House sponsors of H.R. 7050 - the Substance Use Disorder (SUD) Workforce Act of 2024. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. ASAM joined more than 120 organizations in a statement urging the Biden Administration to finalize federal rules to eliminate menthol cigarettes and flavored cigars.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY24 and FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 and FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its recent rules proposing policy changes in 2025 Medicare Advantage (MA) plans. ASAM joined coalition letter asking the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to change Medicare's custody definition to permit coverage for older adults and people with disabilities who are living in the community after incarceration or have other history with the criminal legal system. ASAM sent a letter to Senators Tammy Baldwin and Shelley Moore Capito with several other organizations, advocating the Senators oppose the addition of any language that would prohibit the National Institute on Drug Abuse (NIDA) from funding any research related to harm reduction in the Statement of Managers accompanying the Conference Agreement on the Fiscal 2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. ASAM signed a letter sent to the House sponsors of H.R. 7050 - the Substance Use Disorder (SUD) Workforce Act of 2024. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. ASAM joined more than 120 organizations in a statement urging the Biden Administration to finalize federal rules to eliminate menthol cigarettes and flavored cigars.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY24 and FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 and FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for draft legislation that would provide Medicare coverage for evidence-based residential SUD services. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding its recent rules proposing policy changes in 2025 Medicare Advantage (MA) plans. ASAM joined coalition letter asking the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to change Medicare's custody definition to permit coverage for older adults and people with disabilities who are living in the community after incarceration or have other history with the criminal legal system. ASAM sent a letter to Senators Tammy Baldwin and Shelley Moore Capito with several other organizations, advocating the Senators oppose the addition of any language that would prohibit the National Institute on Drug Abuse (NIDA) from funding any research related to harm reduction in the Statement of Managers accompanying the Conference Agreement on the Fiscal 2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. ASAM signed a letter sent to the House sponsors of H.R. 7050 - the Substance Use Disorder (SUD) Workforce Act of 2024. Suggested additional regulatory changes to SAMHSA related to opioid treatment programs and the provision of methadone for opioid use disorder. ASAM joined more than 120 organizations in a statement urging the Biden Administration to finalize federal rules to eliminate menthol cigarettes and flavored cigars.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Issues related to telehealth and the treatment of opioid use disorder; Issues related to the DEA Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. S. 3193/H.R. 5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office

HR 824 - "Telehealth Benefit Expansion for Workers Act of 2023"; HR 4189 "CONNECT for Health Act of 2023"; S. 2016 "CONNECT for Health Act of 2023"; HR 1843 - "Telehealth Expansion Act of 2023"; S. 1001 - "Telehealth Expansion Act of 2023"; HR 3432 - "Telemental Health Care Access Act of 2023"; HR 5163 "Telehealth Response for E-prescribing Addiction Therapy Services Act"; S. 3193 - "TREATS Act" Implementation of the Ryan Haight Act/DEA rulemaking on telemedicine.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 824 - "Telehealth Benefit Expansion for Workers Act of 2023"; HR 4189 "CONNECT for Health Act of 2023"; S. 2016 "CONNECT for Health Act of 2023"; HR 1843 - "Telehealth Expansion Act of 2023"; S. 1001 - "Telehealth Expansion Act of 2023"; HR 3432 - "Telemental Health Care Access Act of 2023"; HR 5163 "Telehealth Response for E-prescribing Addiction Therapy Services Act"; S. 3193 - "TREATS Act" Implementation of the Ryan Haight Act/DEA rulemaking on telemedicine.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. ASAM joined others in a letter urging Congress to quickly pass legislation to stop another impending round of Medicare payment cuts impacting physicians. Advocated for continued telemedicine flexibilities related to medications for substance use disorder. ASAM sent a letter to the leadership of the U.S. House Committee on Agriculture and the U.S. Senate Committee on Agriculture, Nutrition, and Forestry, supporting the inclusion of the Re-Entry Support Through Opportunities for Resources and Essentials (RESTORE) Act of 2023 (H.R. 3479/S.1753) in the 2023 Farm Bill. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM provided comments to the proposed rule, Requirements Related To the Mental Health Parity and Addiction Equity Act, promulgated by the Department of Health and Human Services (HHS), Employee Benefits Security Administration, and Internal Revenue Service ("2023 Proposed Rule"), as well as comments concerning a related technical release.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)

Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M) Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill. Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine. Supported H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. ASAM joined others in a letter urging Congress to quickly pass legislation to stop another impending round of Medicare payment cuts impacting physicians. Advocated for continued telemedicine flexibilities related to medications for substance use disorder. ASAM sent a letter to the leadership of the U.S. House Committee on Agriculture and the U.S. Senate Committee on Agriculture, Nutrition, and Forestry, supporting the inclusion of the Re-Entry Support Through Opportunities for Resources and Essentials (RESTORE) Act of 2023 (H.R. 3479/S.1753) in the 2023 Farm Bill. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. ASAM provided comments to the proposed rule, Requirements Related To the Mental Health Parity and Addiction Equity Act, promulgated by the Department of Health and Human Services (HHS), Employee Benefits Security Administration, and Internal Revenue Service ("2023 Proposed Rule"), as well as comments concerning a related technical release.

Client expense: $40,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)